Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text

Guidelines and Expert Consensus documents aim to present management and recommendations based on all of the relevant evidence on a particular subject in order to help physicians to select the best possible management strategies for the individual patient, suffering from a specific condition, taking into account not only the impact on outcome, but also the risk–benefit ratio of a particular diagnostic or therapeutic procedure. Numerous studies have demonstrated that patient outcomes improve when evidence-based guideline recommendations are applied in clinical practice. A great number of Guidelines and Expert Consensus Documents have been issued in recent years by the European Society of Cardiology (ESC) and also by other organizations or related societies. The profusion of documents can question the authority and credibility of guidelines, particularly if discrepancies appear between different documents on the same issue leading to confusion for practising physicians. In order to avoid these pitfalls, the ESC and other organizations have issued recommendations for formulating and issuing Guidelines and Expert Consensus Documents. The ESC recommendations for guidelines production can be found on the ESC website. It is beyond the scope of this preamble to recall all, but the basic rules. In brief, the ESC appoints experts in the field to carry out a comprehensive review of the literature, with a view to making a critical evaluation of the use of diagnostic and therapeutic procedures, and assessing the risk–benefit ratio of the therapies recommended for management and/or prevention of a given condition. Estimates of expected health outcomes are included, where data exists. The strength of evidence for or against particular procedures or treatments is weighed, according to predefined scales for grading recommendations and levels of evidence, as outlined below. The Task Force members of the writing panels, as well as the document reviewers, are asked to provide disclosure statements of …

Greet Van den Berghe | Peter Lindgren | Ilse Vanhorebeek | Silvia G. Priori | Bengt Jonsson | Marco Stramba-Badiale | John Camm | Eberhard Standl | John Betteridge | Erland Erdmann | Klaus G. Parhofer | Qing Qiao | Jaakko Tuomilehto | Massimo Volpe | Lars Rydén | M. Laakso | J. Camm | K. Dickstein | S. Priori | D. Wood | J. Tuomilehto | L. Rydén | J. Tamargo | J. Blanc | A. Budaj | Verónica Dean | J. Deckers | J. Lekakis | K. Mcgregor | M. Metra | J. Morais | A. Osterspey | J. Zamorano | K. Malmberg | E. Erdmann | M. Bertrand | M. Volpe | I. Vanhorebeek | B. Charbonnel | A. Flyvbjerg | I. Raz | G. Schernthaner | K. Parhofer | E. Standl | F. Cosentino | J. Östergren | M. Stramba-Badiale | Q. Qiao | H. Gohlke | J. Betteridge | Jean Jacques Blanc | John Lekakis | João Morais | Andrzej Budaj | Keith McGregor | Jaap W. Deckers | Markku Laakso | B. Jônsson | Itamar Raz | José Luis Zamorano | J. W. Deckers | Allan Flyvbjerg | Juan Tamargo | Guntram Schernthaner | Kalevi Pyörälä | Veronica Dean | Kenneth Dickstein | Francesco Cosentino | Jan Östergren | Klas Malmberg | Marco Metra | Ady Osterspey | Michel E. Bertrand | I. Thrainsdottir | Helmut Gohlke | Malgorzata Bartnik | Menko-Jan de Boer | Inga Thrainsdottir | Bernard Charbonnel | Eie Ferrannini | Jose Ramon Gonzalez Juanatey | Ian D. Graham | Pedro Filipe Monteiro | David A. Wood | G. Berghe | P. Lindgren | M. Bartnik | I. Graham | P. Monteiro | M. Boer | J. W. Deckers | K. Pyörälä | J. Juanatey | E. Ferrannini | V. Dean

[1]  M. Venermo,et al.  Treatment of diabetic foot ulcers. , 2009, The Journal of cardiovascular surgery.

[2]  J. Bottomley,et al.  Economic costs of diabetes in the US in 2007 — Implications for Europe , 2008 .

[3]  B. Balkau The decode study , 2008 .

[4]  W. Howard Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes: The Treating to New Targets (TNT) study , 2008 .

[5]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[6]  L. Rydén,et al.  Management of coronary artery disease in patients with and without diabetes mellitus. Acute management reasonable but secondary prevention unacceptably poor: a report from the Euro Heart Survey on Diabetes and the heart , 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[7]  J. Leahy Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial , 2007 .

[8]  A. Ford,et al.  Primary Prevention of Ischaemic Stroke , 2007 .

[9]  Miet Schetz,et al.  Strict blood glucose control with insulin during intensive care after cardiac surgery: impact on 4-years survival, dependency on medical care, and quality-of-life. , 2006, European heart journal.

[10]  J. Ottervanger,et al.  Treatment decisions in stable coronary artery disease: insights from the Euro Heart Survey on Coronary Revascularization. , 2006, The Journal of thoracic and cardiovascular surgery.

[11]  S. Yusuf,et al.  Effect of ramipril on the incidence of diabetes. , 2006, The New England journal of medicine.

[12]  M. Laakso,et al.  Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial , 2006, The Lancet.

[13]  L. Rydén,et al.  Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart , 2006, Heart.

[14]  Samuel Wann,et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committ , 2006, European heart journal.

[15]  Peter Jüni,et al.  Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. , 2006, American heart journal.

[16]  Patrick W Serruys,et al.  The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase. , 2006, American heart journal.

[17]  Glen P. Kenny,et al.  Physical Activity/Exercise and Type 2 Diabetes , 2006, Diabetes Care.

[18]  J. Hsia,et al.  Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes , 2006, Diabetes Care.

[19]  G. Van den Berghe,et al.  Intensive insulin therapy in the medical ICU. , 2006, The New England journal of medicine.

[20]  Patrice Cacoub,et al.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. , 2006, The New England journal of medicine.

[21]  M. Mclean,et al.  The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. , 2006, Diabetes care.

[22]  Jaakko Tuomilehto,et al.  Disorders of glucose metabolism in acute stroke patients: an underrecognized problem. , 2006, Diabetes care.

[23]  Alice Stanton,et al.  Differential Impact of Blood Pressure–Lowering Drugs on Central Aortic Pressure and Clinical Outcomes: Principal Results of the Conduit Artery Function Evaluation (CAFE) Study , 2006, Circulation.

[24]  B. Mitchell,et al.  Screening for silent coronary heart disease in type 2 diabetes: clinical application of American Diabetes Association guidelines. , 2006, Diabetes care.

[25]  N. Clark,et al.  Standards of Medical Care in Diabetes: Response to Power , 2006 .

[26]  Philip P Goodney,et al.  Current status of carotid artery stenting. , 2006, Journal of vascular surgery.

[27]  J. Leahy The Metabolic Syndrome: Time for a Critical Appraisal: Joint Statement From the American Diabetes Association and the European Association for the Study of Diabetes , 2006 .

[28]  C. Snehalatha,et al.  The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1) , 2006, Diabetologia.

[29]  B. Zinman,et al.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.

[30]  Mark Woodward,et al.  Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies , 2005, BMJ : British Medical Journal.

[31]  Seppo Lehto,et al.  Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. , 2005, Diabetes care.

[32]  F. Vancheri,et al.  Impaired glucose metabolism in patients with acute stroke and no previous diagnosis of diabetes mellitus. , 2005, QJM : monthly journal of the Association of Physicians.

[33]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[34]  S. Shinnar,et al.  The trials and tribulations of pediatric drug trials , 2005, Neurology.

[35]  S. Kaplan,et al.  Longitudinal assessment of quality of life in patients with type 2 diabetes and self-reported erectile dysfunction. , 2005, Diabetes care.

[36]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[37]  F. Fernández‐Avilés,et al.  Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients: The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial , 2005, Circulation.

[38]  V. Gudnason,et al.  Glucose abnormalities and heart failure predict poor prognosis in the population-based Reykjavik Study , 2005, European Journal of Cardiovascular Prevention & Rehabilitation.

[39]  J. Tuomilehto,et al.  The validity of the Finnish Diabetes Risk Score for the prediction of the incidence of coronary heart disease and stroke, and total mortality , 2005, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[40]  T. Rea,et al.  Diabetes, glucose level, and risk of sudden cardiac death. , 2005, European heart journal.

[41]  E. Frank Book Review Women's Mental Health: A Life-Cycle Approach Edited by Sarah E. Romans and Mary V. Seeman. 414 pp. Philadelphia, Lippincott Williams & Wilkins, 2005. $59.95. 0-7817-5129-2 , 2005 .

[42]  Paul Zimmet,et al.  The metabolic syndrome—a new worldwide definition , 2005, The Lancet.

[43]  R. Collins,et al.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri , 2005, The Lancet.

[44]  L. Rydén,et al.  Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes: a report from the GAMI study , 2005, Diabetologia.

[45]  C. Imray,et al.  Are some strokes preventable? The potential role of transcranial doppler in transient ischaemic attacks of carotid origin , 2005, The Lancet Neurology.

[46]  Richard Kahn,et al.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. , 2005, Diabetes care.

[47]  P. Serruys,et al.  Comparison of short- (one month) and long- (twelve months) term outcomes of sirolimus- versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries). , 2005, American Journal of Cardiology.

[48]  Ilse Vanhorebeek,et al.  Intensive insulin therapy protects the endothelium of critically ill patients. , 2005, The Journal of clinical investigation.

[49]  E. Gale The myth of the metabolic syndrome , 2005, Diabetologia.

[50]  J Herlitz,et al.  Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. , 2005, European heart journal.

[51]  M. Simoons,et al.  The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. , 2005, European heart journal.

[52]  D. E. Mathis,et al.  Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2005, Archives of internal medicine.

[53]  S. Yusuf,et al.  Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. , 2005, JAMA.

[54]  L. Landsberg Insulin resistance and the metabolic syndrome , 2005, Diabetologia.

[55]  J. Ottervanger,et al.  Comparison of myocardial perfusion after successful primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction with versus without diabetes mellitus. , 2005, The American journal of cardiology.

[56]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[57]  L. Bouter,et al.  Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. , 2005, Diabetes care.

[58]  B. Gersh,et al.  Methods of coronary revascularization--things may not be as they seem. , 2005, The New England journal of medicine.

[59]  E. Hannan,et al.  Outcomes of planned home births with certified professional midwives: large prospective study in North America , 2005, BMJ : British Medical Journal.

[60]  Andrew Briggs,et al.  Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20 536 individuals , 2005, The Lancet.

[61]  M. Bartnik Glucose regulation and coronary artery disease : Studies on prevalence, recognition and prognostic implications , 2005 .

[62]  J. Tuomilehto,et al.  Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome , 2005, Diabetes & vascular disease research.

[63]  Gianni Tognoni,et al.  Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study. , 2005, Diabetes care.

[64]  F Bruyninckx,et al.  Insulin therapy protects the central and peripheral nervous system of intensive care patients , 2005, Neurology.

[65]  R. Holman,et al.  Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72) , 2005, Diabetologia.

[66]  K. Narayan,et al.  Trends in cardiovascular complications of diabetes. , 2005, JAMA.

[67]  J. Tuomilehto,et al.  Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction , 2005, Diabetologia.

[68]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[69]  M. Hanefeld,et al.  A long‐term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double‐blind, parallel‐group comparison trial , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[70]  S. Fowler,et al.  Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. , 2005, Diabetes care.

[71]  L. Chambless,et al.  Diabetes, glucose, insulin, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study. , 2005, Diabetes care.

[72]  Vilmundur Gudnason,et al.  The association between glucose abnormalities and heart failure in the population-based Reykjavik study. , 2005, Diabetes care.

[73]  I. Palacios,et al.  Drug-eluting stents for diabetes mellitus: a rush to judgment? , 2005, Journal of the American College of Cardiology.

[74]  L. Rydén,et al.  Tissue Doppler imaging for the detection and quantitation of myocardial dysfunction in patients with type 2 diabetes mellitus , 2005, Diabetes & vascular disease research.

[75]  W. Tamborlane,et al.  The normal glucose tolerance continuum in obese youth: evidence for impairment in beta-cell function independent of insulin resistance. , 2005, The Journal of clinical endocrinology and metabolism.

[76]  Hideo Ayame,et al.  [The Da Qing IGT and Diabetes study]. , 2005, Nihon rinsho. Japanese journal of clinical medicine.

[77]  Dick M. Goedhart,et al.  Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention--a Lescol Intervention Prevention Study (LIPS) substudy. , 2005, American heart journal.

[78]  Kathryn Tan,et al.  Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966–2004)* , 2005, Current medical research and opinion.

[79]  Maria Inês Schmidt,et al.  The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. , 2005, Diabetes care.

[80]  Jun Zhu,et al.  Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. , 2005, JAMA.

[81]  P. Dyck,et al.  Sudden cardiac death in diabetes mellitus: risk factors in the Rochester diabetic neuropathy study , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[82]  C. Wolf‐peeters,et al.  Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients , 2005, The Lancet.

[83]  P. Clemmensen,et al.  The prognostic value of pre-discharge exercise testing after myocardial infarction treated with either primary PCI or fibrinolysis: a DANAMI-2 sub-study. , 2004, European heart journal.

[84]  K. Swedberg,et al.  [Expert Consensus document on beta-adrenergic receptor blockers]. , 2004, Revista espanola de cardiologia.

[85]  J. Wilberger,et al.  The impact of hyperglycemia on patients with severe brain injury. , 2005, The Journal of trauma.

[86]  P. Deedwania,et al.  Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. , 2005, American heart journal.

[87]  G. Fonarow,et al.  Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. , 2005, American heart journal.

[88]  R. Hall,et al.  The Coronary Artery Revascularisation in Diabetes (CARDia) trial: background, aims, and design. , 2005, American heart journal.

[89]  Masafumi Matsuda,et al.  beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. , 2005, The Journal of clinical endocrinology and metabolism.

[90]  M. Apkon,et al.  Persistent hyperglycemia in critically ill children. , 2005, The Journal of pediatrics.

[91]  S. Yusuf,et al.  Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes. , 2005, Canadian journal of physiology and pharmacology.

[92]  C. van Weel,et al.  Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. , 2005, Diabetes care.

[93]  M. Laakso,et al.  Proteinuria and metabolic syndrome as predictors of cardiovascular death in non-diabetic and type 2 diabetic men and women , 2005, Diabetologia.

[94]  D. Lawlor,et al.  Does the new International Diabetes Federation definition of the metabolic syndrome predict CHD any more strongly than older definitions? Findings from the British Women’s Heart and Health Study , 2005, Diabetologia.

[95]  Zygimantas Cepaitis,et al.  Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. , 2005, Diabetes.

[96]  M. Engelgau,et al.  Prevention of type 2 diabetes: issues and strategies for identifying persons for interventions. , 2004, Diabetes technology & therapeutics.

[97]  Y. Seino,et al.  Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. , 2004, Diabetes research and clinical practice.

[98]  V. Legrand,et al.  Drug-eluting stents: meta-analysis in diabetic patients. , 2004, European heart journal.

[99]  M. Hanefeld,et al.  Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. , 2004, The Journal of clinical endocrinology and metabolism.

[100]  G Hu,et al.  Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study , 2004, Diabetologia.

[101]  Seppo Lehto,et al.  Gender difference in the impact of type 2 diabetes on coronary heart disease risk. , 2004, Diabetes care.

[102]  G. Radda,et al.  Uncoupling proteins in human heart , 2004, The Lancet.

[103]  G. Remuzzi,et al.  Preventing microalbuminuria in type 2 diabetes. , 2004, The New England journal of medicine.

[104]  S. Haffner,et al.  Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? , 2004, Diabetes care.

[105]  S. Colagiuri The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. , 2004, European heart journal.

[106]  M. Olschewski,et al.  Glucose-insulin-potassium in cardiac surgery: a meta-analysis. , 2004, The Annals of thoracic surgery.

[107]  C. Edwards International Textbook of Diabetes Mellitus , 2004 .

[108]  Roberto Ferrari,et al.  The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. , 2004, European heart journal.

[109]  F. Lobo,et al.  Direct health care costs of diabetic patients in Spain. , 2004, Diabetes care.

[110]  M. Hanefeld,et al.  Postprandial glucose regulation and diabetic complications. , 2004, Archives of internal medicine.

[111]  Deepak L. Bhatt,et al.  Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. , 2004, Archives of internal medicine.

[112]  B. Gage,et al.  Selecting Patients With Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin , 2004, Circulation.

[113]  L. Rydén,et al.  Abnormal glucose tolerance – a common risk factor in patients with acute myocardial infarction in comparison with population‐based controls , 2004, Journal of internal medicine.

[114]  Carmen Castaneda-Sceppa,et al.  Physical activity/exercise and type 2 diabetes. , 2004, Diabetes care.

[115]  Neil R. Powe,et al.  Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus , 2004, Annals of Internal Medicine.

[116]  N. Day,et al.  Association of Hemoglobin A1c with Cardiovascular Disease and Mortality in Adults: The European Prospective Investigation into Cancer in Norfolk , 2004, Annals of Internal Medicine.

[117]  S. Solomon,et al.  Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction: The Valsartan in Acute Myocardial Infarction (VALIANT) Trial , 2004, Circulation.

[118]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[119]  Ken Williams,et al.  National Cholesterol Education Program Versus World Health Organization Metabolic Syndrome in Relation to All-Cause and Cardiovascular Mortality in the San Antonio Heart Study , 2004, Circulation.

[120]  D. Singer,et al.  Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[121]  H. Taegtmeyer Cardiac metabolism as a target for the treatment of heart failure. , 2004, Circulation.

[122]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[123]  Christopher P Cannon,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[124]  J. Tuomilehto,et al.  Occupational, Commuting, and Leisure-Time Physical Activity in Relation to Total and Cardiovascular Mortality Among Finnish Subjects With Type 2 Diabetes , 2004, Circulation.

[125]  K. Lachapelle,et al.  Maintenance of Normoglycemia During Cardiac Surgery , 2004, Anesthesia and analgesia.

[126]  C. Gullion,et al.  The incidence of congestive heart failure in type 2 diabetes: an update. , 2004, Diabetes care.

[127]  James Stephen Krinsley,et al.  Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. , 2004, Mayo Clinic proceedings.

[128]  G. Sundkvist,et al.  A 14‐year prospective study of autonomic nerve function in Type 1 diabetic patients: association with nephropathy , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[129]  E. Barrett,et al.  Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. , 2004, Diabetes care.

[130]  H. Diener,et al.  Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial , 2004, The Lancet.

[131]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[132]  J. Gore,et al.  Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. , 2004, Archives of internal medicine.

[133]  D. Ziegler,et al.  Stroke in patients with diabetes mellitus , 2004, Diabetes/metabolism research and reviews.

[134]  L. Rydén,et al.  Effects of Trimetazidine on Left Ventricular Function in Patients with Type 2 Diabetes and Heart Failure , 2004, Journal of cardiovascular pharmacology.

[135]  D. Bacquer,et al.  Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys , 2004, Diabetologia.

[136]  I. Godsland,et al.  Loss of beta cell function as fasting glucose increases in the non-diabetic range , 2004, Diabetologia.

[137]  Neil J Grey,et al.  Reduction of nosocomial infections in the surgical intensive-care unit by strict glycemic control. , 2004, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[138]  Yingxing Wu,et al.  Effect of hyperglycemia and continuous intravenous insulin infusions on outcomes of cardiac surgical procedures: the Portland Diabetic Project. , 2004, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[139]  J. Tuomilehto,et al.  Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. , 2004, Archives of internal medicine.

[140]  J Wayne Meredith,et al.  Relationship of early hyperglycemia to mortality in trauma patients. , 2004, The Journal of trauma.

[141]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[142]  A. Ceriello,et al.  Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[143]  T. Valle,et al.  Physical activity, body mass index, and risk of type 2 diabetes in patients with normal or impaired glucose regulation. , 2004, Archives of internal medicine.

[144]  G. Stone,et al.  Short- and long-term results after multivessel stenting in diabetic patients. , 2004, Journal of the American College of Cardiology.

[145]  K. Narayan,et al.  Epidemiology and geography of type 2 diabetes mellitus , 2004 .

[146]  E. Ford The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. , 2004, Atherosclerosis.

[147]  N. Lamblin,et al.  Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. , 2004, European heart journal.

[148]  G. Albers,et al.  Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. , 2004, Journal of the American College of Cardiology.

[149]  M. Borger,et al.  Prevention and management of deep sternal wound infection. , 2004, Seminars in thoracic and cardiovascular surgery.

[150]  Bendix Carstensen,et al.  A Danish diabetes risk score for targeted screening: the Inter99 study. , 2004, Diabetes care.

[151]  K. Malmberg,et al.  Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. , 2004, Journal of the American College of Cardiology.

[152]  R. Frye,et al.  Comparison of survival after successful percutaneous coronary intervention of patients with diabetes mellitus receiving insulin versus those receiving only diet and/or oral hypoglycemic agents. , 2004, American Journal of Cardiology.

[153]  A. Chinaglia,et al.  QT interval, cardiovascular risk factors and risk of death in diabetes , 2004, Journal of endocrinological investigation.

[154]  E. Topol,et al.  Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. , 2004, European heart journal.

[155]  E. Mannarino,et al.  Familial HDL deficiency due to ABCA1 gene mutations with or without other genetic lipoprotein disorders. , 2004, Atherosclerosis.

[156]  O. Schnell,et al.  Hospital outcome of acute myocardial infarction in patients with and without diabetes mellitus , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[157]  Oliver Schnell,et al.  Intensification of therapeutic approaches reduces mortality in diabetic patients with acute myocardial infarction: the Munich registry. , 2004, Diabetes care.

[158]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Circulation.

[159]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[160]  R. Detrano,et al.  Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. , 2004, JAMA.

[161]  E. Bonora,et al.  The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[162]  Darren K Mcguire,et al.  Influence of diabetes on long‐term outcome among unselected patients with acute coronary events , 2004, Scandinavian cardiovascular journal : SCJ.

[163]  S. Priori,et al.  2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension , 2004, Heart Drug.

[164]  A. K. Jonassen,et al.  Glucose-Insulin-Potassium Reduces Infarct Size When Administered During Reperfusion , 2000, Cardiovascular Drugs and Therapy.

[165]  B. Rodrigues,et al.  Metabolic disturbances in diabetic cardiomyopathy , 1998, Molecular and Cellular Biochemistry.

[166]  K. Asplund,et al.  Diabetes as a risk factor for stroke. A population perspective , 1995, Diabetologia.

[167]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[168]  D. Toni,et al.  Does hyperglycaemia play a role on the outcome of acute ischaemic stroke patients? , 1992, Journal of Neurology.

[169]  K. Eriksson,et al.  Prevention of Type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise The 6-year Malmö feasibility study , 1991, Diabetologia.

[170]  S. Haffner,et al.  Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome , 1991, Diabetologia.

[171]  D. Ewing,et al.  Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients , 1991, Diabetologia.

[172]  D. Giugliano,et al.  Evidence for a hyperglycaemia-dependent decrease of antithrombin III-thrombin complex formation in humans , 1990, Diabetologia.

[173]  F. Cambien,et al.  Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes , 1989, Diabetologia.

[174]  P. Bennett,et al.  Medial arterial calcification and its association with mortality and complications of diabetes , 1988, Diabetologia.

[175]  Thomas R. Riley,et al.  A Randomized Double-blind Placebo-controlled Trial , 2004 .

[176]  Dieter Mesotten,et al.  Contribution of circulating lipids to the improved outcome of critical illness by glycemic control with intensive insulin therapy. , 2004, The Journal of clinical endocrinology and metabolism.

[177]  K. Swedberg,et al.  Expert consensus document on beta-adrenergic receptor blockers. , 2004, European heart journal.

[178]  M. Hanefeld,et al.  Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. , 2004, European heart journal.

[179]  N. Gratsianskiĭ [Expert consensus document on the use of antiplatelet agents]. , 2004, Kardiologiia.

[180]  R. de Caterina,et al.  Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. , 2004, European heart journal.

[181]  G. Nijpels,et al.  The performance of a risk score as a screening test for undiagnosed hyperglycemia in ethnic minority groups: data from the 1999 health survey for England. , 2004, Diabetes care.

[182]  G. Van den Berghe How does blood glucose control with insulin save lives in intensive care? , 2004, The Journal of clinical investigation.

[183]  N. Doll,et al.  Impact of Diabetes Mellitus on Cardiac Surgery Outcome , 2003, The Thoracic and cardiovascular surgeon.

[184]  T. Evans,et al.  Glucose control and mortality in critically ill patients. , 2004, JAMA.

[185]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2004, European heart journal.

[186]  Diederick Grobbee,et al.  Randomized Comparison Between Stenting and Off-Pump Bypass Surgery in Patients Referred for Angioplasty , 2003, Circulation.

[187]  K. Borch-Johnsen,et al.  Hypertension in people with Type 2 diabetes: knowledge‐based diabetes‐specific guidelines , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[188]  G. Van den Berghe,et al.  Metabolic, endocrine, and immune effects of stress hyperglycemia in a rabbit model of prolonged critical illness. , 2003, Endocrinology.

[189]  R. Schiele,et al.  Intensive treatment of coronary artery disease in diabetic patients in clinical practice: results of the MITRA study , 2003, Acta Diabetologica.

[190]  James Stephen Krinsley,et al.  Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. , 2003, Mayo Clinic proceedings.

[191]  Jaakko Tuomilehto,et al.  The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. , 2003, Diabetes care.

[192]  E. Mayer-Davis,et al.  Nutrition and prevention of type 2 diabetes. , 2003, Annual review of nutrition.

[193]  Tom Fahey,et al.  Predictive accuracy of the Framingham coronary risk score in British men:prospective cohort study , 2003, BMJ : British Medical Journal.

[194]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[195]  J. Shaw,et al.  Follow-up report on the diagnosis of diabetes mellitus. , 2003, Diabetes care.

[196]  L. Monti,et al.  Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. , 2003, American heart journal.

[197]  T. Vos,et al.  Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. , 2003, American heart journal.

[198]  D. Mikhailidis,et al.  Early Benefit from Structured Care with Atorvastatin in Patients with Coronary Heart Disease and Diabetes Mellitus , 2003, Angiology.

[199]  J. Tu,et al.  Risk Factors for Death or Stroke After Carotid Endarterectomy: Observations From the Ontario Carotid Endarterectomy Registry , 2003, Stroke.

[200]  M. Pfeffer,et al.  Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. , 2003, Journal of the American College of Cardiology.

[201]  E. Antman Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: appropriate interpretation of the guidelines. , 2003, American heart journal.

[202]  Richard Hellman,et al.  American College of Endocrinology position statement on the insulin resistance syndrome. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[203]  J. Tuomilehto,et al.  Predictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow-up. , 2003, Diabetes care.

[204]  D. Kereiakes,et al.  Metabolic syndrome epidemic. , 2003, Circulation.

[205]  J. Beckman,et al.  Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I , 2013, European heart journal.

[206]  K. Fox,et al.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) , 2003, The Lancet.

[207]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[208]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[209]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol european trial (COMET): randomized controlled trial☆ , 2003 .

[210]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2003 .

[211]  H. Diener,et al.  European Stroke Initiative Recommendations for Stroke Management – Update 2003 , 2003, Cerebrovascular Diseases.

[212]  M. Blombäck,et al.  Effect of dalteparin on healing of chronic foot ulcers in diabetic patients with peripheral arterial occlusive disease: a prospective, randomized, double-blind, placebo-controlled study. , 2003, Diabetes care.

[213]  Ralph B D'Agostino,et al.  A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. , 2003, JAMA.

[214]  B. Horne,et al.  Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. , 2003, American heart journal.

[215]  G. De Backer,et al.  Predictive value of classical risk factors and their control in coronary patients: a follow-up of the EUROASPIRE I cohort , 2003, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[216]  Markolf Hanefeld,et al.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. , 2003, JAMA.

[217]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.

[218]  G. Tinkoff,et al.  Admission hyperglycemia as a prognostic indicator in trauma. , 2003, The Journal of trauma.

[219]  S. Mudaliar,et al.  Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. , 2003, Diabetes care.

[220]  Carl J Caspersen,et al.  Relationship of walking to mortality among US adults with diabetes. , 2003, Archives of internal medicine.

[221]  G. L’italien,et al.  Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. , 2003, The American journal of cardiology.

[222]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[223]  J. Saver A comparison of risk factors for recurrent TIA and stroke in patients diagnosed with TIA , 2003, Neurology.

[224]  H. Tunstall-Pedoe,et al.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.

[225]  Beverley Balkau,et al.  Age- and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. , 2003, Diabetes care.

[226]  E. Rimm,et al.  Physical Activity in Relation to Cardiovascular Disease and Total Mortality Among Men With Type 2 Diabetes , 2003, Circulation.

[227]  G. Hu,et al.  Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes , 2003, Diabetologia.

[228]  C. Cogbill,et al.  Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform? , 2003, Journal of the American College of Cardiology.

[229]  K. Malmberg,et al.  Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction. , 2003, European heart journal.

[230]  E. Guallar,et al.  Meta-Analysis of Randomized Educational and Behavioral Interventions in Type 2 Diabetes , 2003, The Diabetes educator.

[231]  Helmut Schulte,et al.  Framingham risk function overestimates risk of coronary heart disease in men and women from Germany--results from the MONICA Augsburg and the PROCAM cohorts. , 2003, European heart journal.

[232]  K. Forrest,et al.  Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. , 2003, Diabetes care.

[233]  JoAnn E. Manson,et al.  Prospective Study of Sudden Cardiac Death Among Women in the United States , 2003, Circulation.

[234]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[235]  J. Tuomilehto,et al.  The major diabetes prevention trials , 2003, Current diabetes reports.

[236]  Z. Bloomgarden American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC. , 2003, Diabetes care.

[237]  G. Van den Berghe,et al.  Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. , 2003, The Journal of clinical endocrinology and metabolism.

[238]  P Ducimetière,et al.  Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. , 2003, European heart journal.

[239]  Jaakko Tuomilehto,et al.  The diabetes risk score: a practical tool to predict type 2 diabetes risk. , 2003, Diabetes care.

[240]  C. Palmer,et al.  Outcomes With Nifedipine GITS or Co-Amilozide in Hypertensive Diabetics and Nondiabetics in Intervention as a Goal in Hypertension (INSIGHT) , 2003, Hypertension.

[241]  Claude Colette,et al.  Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). , 2003, Diabetes care.

[242]  B. Howard,et al.  Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: the Strong Heart Study. , 2003, Diabetes care.

[243]  Plamen Nikolov,et al.  Economic Costs of Diabetes in the U.S. in 2002 , 2003, Diabetes care.

[244]  T. Lüscher,et al.  High Glucose Causes Upregulation of Cyclooxygenase-2 and Alters Prostanoid Profile in Human Endothelial Cells: Role of Protein Kinase C and Reactive Oxygen Species , 2003, Circulation.

[245]  Shankuan Zhu,et al.  The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. , 2003, Archives of internal medicine.

[246]  H. Löwel,et al.  High prevalence of undiagnosed diabetes mellitus in Southern Germany: Target populations for efficient screening. The KORA survey 2000 , 2003, Diabetologia.

[247]  T. Valle,et al.  Occupational, commuting, and leisure-time physical activity in relation to risk for Type 2 diabetes in middle-aged Finnish men and women , 2003, Diabetologia.

[248]  D. Moliterno,et al.  Diabetes and percutaneous coronary intervention: the sweet smell of success? , 2003, American heart journal.

[249]  B. Rutherford,et al.  Diabetes mellitus is associated with a shift in the temporal risk profile of inhospital death after percutaneous coronary intervention: an analysis of 25,223 patients over 20 years. , 2003, American heart journal.

[250]  Miet Schetz,et al.  Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control* , 2003, Critical care medicine.

[251]  B. Lüderitz,et al.  Atrial fibrillation: relation between clinical risk factors and transoesophageal echocardiographic risk factors for thromboembolism , 2003, Heart.

[252]  Matthijs Oudkerk,et al.  Incidence and Risk Factors of Silent Brain Infarcts in the Population-Based Rotterdam Scan Study , 2003, Stroke.

[253]  N. Waugh,et al.  Mortality From Cerebrovascular Disease in a Cohort of 23 000 Patients With Insulin-Treated Diabetes , 2003, Stroke.

[254]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[255]  Nancy R Cook,et al.  C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.

[256]  E. Vittinghoff,et al.  Glycemic Effects of Postmenopausal Hormone Therapy: The Heart and Estrogen/progestin Replacement Study: A Randomized, Double-Blind, Placebo-Controlled Trial , 2003, Annals of Internal Medicine.

[257]  Sankey V. Williams,et al.  ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). , 2003, Circulation.

[258]  T. Marwick,et al.  Effects of glucose–insulin–potassium infusion on chronic ischaemic left ventricular dysfunction , 2003, Heart.

[259]  N. Maurits,et al.  Admitting Acute Ischemic Stroke Patients to a Stroke Care Monitoring Unit Versus a Conventional Stroke Unit: A Randomized Pilot Study , 2003, Stroke.

[260]  Robert M. Anderson,et al.  Prevention or delay of type 2 diabetes. , 2004, Diabetes care.

[261]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[262]  T.,et al.  American Association of Clinical Endocrinologists (AACE) Consensus Conference on the Insulin Resistance Syndrome , 2003 .

[263]  M. Massi-Benedetti,et al.  The Costs of Type 2 Diabetes Mellitus in Italy , 2003, Treatments in endocrinology.

[264]  J. Tuomilehto,et al.  Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? , 2003, Diabetes care.

[265]  P. Nilsson,et al.  Hypertension in diabetes: trends in clinical control in repeated large-scale national surveys from Sweden , 2003, Journal of Human Hypertension.

[266]  W. Weaver,et al.  Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. , 2003, American heart journal.

[267]  G. Gallus,et al.  Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. , 2003, Diabetes care.

[268]  B. Zinman,et al.  Physical activity/exercise and diabetes mellitus. , 2003, Diabetes care.

[269]  A. Barcelo,et al.  The cost of diabetes in Latin America and the Caribbean. , 2003, Bulletin of the World Health Organization.

[270]  E. Falk,et al.  Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. , 2003, European heart journal.

[271]  Arshag D Mooradian,et al.  Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. , 2003, Diabetes care.

[272]  E. Standl,et al.  The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type II diabetes mellitus , 2003, Diabetologia.

[273]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[274]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[275]  James W. Anderson,et al.  Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). , 2002, Archives of internal medicine.

[276]  L. Wallentin,et al.  A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study. , 2002, Journal of the American College of Cardiology.

[277]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[278]  G. Specchia,et al.  Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2002, European heart journal.

[279]  R. Macko,et al.  Thrombomodulin deficiency in human diabetic nerve microvasculature. , 2002, Diabetes.

[280]  F. Murad,et al.  Protein Nitration in Cardiovascular Diseases , 2002, Pharmacological Reviews.

[281]  F. Cappuccio,et al.  Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice: cross sectional population based study , 2002, BMJ : British Medical Journal.

[282]  R. Frye,et al.  Coronary Bypass Graft Patency in Patients With Diabetes in the Bypass Angioplasty Revascularization Investigation (BARI) , 2002, Circulation.

[283]  A. Jacobs,et al.  Comparison of in-hospital and one-year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). , 2002, The American journal of cardiology.

[284]  Jerome Sacks,et al.  Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry. , 2002, Journal of the American College of Cardiology.

[285]  G. Lip,et al.  Antithrombotic therapy for atrial fibrillation , 2002, BMJ : British Medical Journal.

[286]  S. Yusuf,et al.  Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. , 2002, Diabetes care.

[287]  P. Nilsson,et al.  Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. , 2002, Diabetes & metabolism.

[288]  E. Antman,et al.  Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy. , 2002, American heart journal.

[289]  G. Chatellier,et al.  The Framingham prediction rule is not valid in a European population of treated hypertensive patients , 2002, Journal of hypertension.

[290]  P. Iozzo,et al.  Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. , 2002, Diabetes.

[291]  P. Iozzo,et al.  Mismatch between insulin-mediated glucose uptake and blood flow in the heart of patients with Type II diabetes , 2002, Diabetologia.

[292]  Catherine Kim,et al.  Gestational diabetes and the incidence of type 2 diabetes: a systematic review. , 2002, Diabetes care.

[293]  Curt D. Furberg,et al.  Incidence, Manifestations, and Predictors of Brain Infarcts Defined by Serial Cranial Magnetic Resonance Imaging in the Elderly: The Cardiovascular Health Study , 2002, Stroke.

[294]  Ameet Bakhai,et al.  Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial , 2002, The Lancet.

[295]  Deepak L. Bhatt,et al.  Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. , 2002, The American journal of cardiology.

[296]  K. Dickstein,et al.  Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial , 2002, The Lancet.

[297]  J. Killian,et al.  Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. , 2002, Journal of the American College of Cardiology.

[298]  L. Hsu,et al.  Clinical outcomes of patients with diabetes mellitus and acute myocardial infarction treated with primary angioplasty or fibrinolysis , 2002, Heart.

[299]  S. Marso Optimizing the diabetic formulary: beyond aspirin and insulin. , 2002, Journal of the American College of Cardiology.

[300]  P. Tsao,et al.  Impaired Nitric Oxide Synthase Pathway in Diabetes Mellitus: Role of Asymmetric Dimethylarginine and Dimethylarginine Dimethylaminohydrolase , 2002, Circulation.

[301]  Jeffrey L Carson,et al.  Diabetes mellitus increases short-term mortality and morbidity in patients undergoing coronary artery bypass graft surgery. , 2002, Journal of the American College of Cardiology.

[302]  H. Gerstein,et al.  The Economic Cost of Diabetes in Canada, 1998 , 2002 .

[303]  T. Jørgensen,et al.  A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. , 2002, International journal of epidemiology.

[304]  M L Simoons,et al.  A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). , 2002, European heart journal.

[305]  U. Das Is insulin an endogenous cardioprotector? , 2002, Critical care.

[306]  M. Gheorghiade,et al.  &bgr;-Blockers in the Post-Myocardial Infarction Patient , 2002, Circulation.

[307]  P. Herrero,et al.  Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[308]  AndrewJ. S. Coats MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[309]  G. Davey Smith,et al.  Physical activity and cause‐specific mortality in men with Type 2 diabetes/impaired glucose tolerance: evidence from the Whitehall study , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[310]  P. Vokonas,et al.  A comparison of the Framingham and European Society of Cardiology coronary heart disease risk prediction models in the normative aging study. , 2002, American heart journal.

[311]  S. Haffner,et al.  Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. , 2002, Diabetes care.

[312]  Walter C Willett,et al.  Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. , 2002, Diabetes care.

[313]  A. Hamsten,et al.  Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study , 2002, The Lancet.

[314]  M. Laakso,et al.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.

[315]  L. Gaal,et al.  Assessing the impact of complications on the costs of Type II diabetes , 2002, Diabetologia.

[316]  G. Shulman,et al.  Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β‐cell dysfunction , 2002, European journal of clinical investigation.

[317]  R. Bucala,et al.  Advanced glycation end products and endothelial dysfunction in type 2 diabetes. , 2002, Diabetes care.

[318]  L. Wallentin,et al.  Early revascularisation and 1-year survival in 14-day survivors of acute myocardial infarction: a prospective cohort study , 2002, The Lancet.

[319]  Peter Libby,et al.  Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. , 2002, JAMA.

[320]  D. Rader,et al.  Lipases and HDL metabolism , 2002, Trends in Endocrinology & Metabolism.

[321]  Kurt J Greenlund,et al.  Sex Differences in US Mortality Rates for Stroke and Stroke Subtypes by Race/Ethnicity and Age, 1995–1998 , 2002, Stroke.

[322]  K. Channon,et al.  Mechanisms of Increased Vascular Superoxide Production in Human Diabetes Mellitus: Role of NAD(P)H Oxidase and Endothelial Nitric Oxide Synthase , 2002, Circulation.

[323]  S. Haffner,et al.  Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. , 2002, Diabetes.

[324]  F. Gao,et al.  Ischemia-Reperfusion : The Roles of PI 3-Kinase , Akt , and Endothelial Nitric Oxide Nitric Oxide Mediates the Antiapoptotic Effect of Insulin in Myocardial , 2002 .

[325]  Steven Snapinn,et al.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol , 2002, The Lancet.

[326]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[327]  A. Connor,et al.  The way I see it: House officers need formal career development , 2002 .

[328]  N. Vaughan Report of the 8th EASD-DOIT Study Group Workshop "Decision Support in Diabetes Care" Stirling Royal Infirmary, Stirling, UK, 7-8 September 2001. , 2002, Diabetologia.

[329]  M. Franz,et al.  The evidence for the effectiveness of medical nutrition therapy in diabetes management. , 2002, Diabetes care.

[330]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[331]  G. Assmann,et al.  Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Münster (PROCAM) Study , 2002, Circulation.

[332]  G. Rozanski,et al.  A Metabolic Mechanism For Cardiac K+ Channel Remodelling , 2002, Clinical and experimental pharmacology & physiology.

[333]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[334]  R. D'Agostino,et al.  Risk of Hospitalized Stroke in Men Enrolled in the Honolulu Heart Program and the Framingham Study: A Comparison of Incidence and Risk Factor Effects , 2002, Stroke.

[335]  A. Hofman,et al.  Prevalence and Risk Factors of Silent Brain Infarcts in the Population-Based Rotterdam Scan Study , 2002, Stroke.

[336]  B. Howard,et al.  Diabetes and cardiovascular disease , 2000, Annual review of medicine.

[337]  B. Bistrian,et al.  Intensive insulin therapy in critically ill patients. , 2002, The New England journal of medicine.

[338]  S. Yusuf MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[339]  B. Jönsson Revealing the cost of Type II diabetes in Europe. , 2002, Diabetologia.

[340]  Arshag D Mooradian,et al.  Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. , 2002, Diabetes care.

[341]  L. Niskanen,et al.  Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. , 2001, Diabetes care.

[342]  B. Davis,et al.  The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience. , 2001, Controlled clinical trials.

[343]  J. Tayek,et al.  Cortisol increases gluconeogenesis in humans: its role in the metabolic syndrome. , 2001, Clinical science.

[344]  D. Yellon,et al.  Myocardial Protection by Insulin at Reperfusion Requires Early Administration and Is Mediated via Akt and p70s6 Kinase Cell-Survival Signaling , 2001, Circulation research.

[345]  M. Lai,et al.  Direct costs-of-illness of patients with diabetes mellitus in Taiwan. , 2001, Diabetes research and clinical practice.

[346]  S. Dimmeler,et al.  Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. , 2001, The Journal of clinical investigation.

[347]  M. Rich,et al.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. , 2001, JAMA.

[348]  A. Vinik,et al.  Recognizing and treating diabetic autonomic neuropathy. , 2001, Cleveland Clinic journal of medicine.

[349]  E Geraci,et al.  Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart. , 2001, European heart journal.

[350]  V. Fuster,et al.  ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conference , 2001, Circulation.

[351]  H. Gerstein,et al.  Stress Hyperglycemia and Prognosis of Stroke in Nondiabetic and Diabetic Patients: A Systematic Overview , 2001, Stroke.

[352]  R M Heethaar,et al.  Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. , 2001, Diabetes care.

[353]  M. Woodward,et al.  Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .

[354]  A. Sniderman,et al.  Hypertriglyceridemic HyperapoB: The Unappreciated Atherogenic Dyslipoproteinemia in Type 2 Diabetes Mellitus , 2001, Annals of Internal Medicine.

[355]  D. Chinkes,et al.  Association of hyperglycemia with increased mortality after severe burn injury. , 2001, The Journal of trauma.

[356]  M. Mack,et al.  Influence of diabetes on mortality and morbidity: off-pump coronary artery bypass grafting versus coronary artery bypass grafting with cardiopulmonary bypass. , 2001, The Annals of thoracic surgery.

[357]  P. Bennett,et al.  Follow-up of the WHO multinational study of vascular disease in diabetes: general description and morbidity , 2001, Diabetologia.

[358]  H. Keen,et al.  Mortality and causes of death in the WHO multinational study of vascular disease in diabetes , 2001, Diabetologia.

[359]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[360]  A. Boulton,et al.  Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. , 2001, Diabetes care.

[361]  A Hofman,et al.  The prognosis of heart failure in the general population: The Rotterdam Study. , 2001, European heart journal.

[362]  R. Pratley,et al.  The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus , 2001, Diabetologia.

[363]  A. Vinik,et al.  Platelet dysfunction in type 2 diabetes. , 2001, Diabetes care.

[364]  S. Saydah,et al.  Postchallenge hyperglycemia and mortality in a national sample of U.S. adults. , 2001, Diabetes care.

[365]  J. Muller,et al.  Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. , 2001, Diabetes care.

[366]  U Ravens,et al.  Task Force on Sudden Cardiac Death of the European Society of Cardiology. , 2001, European heart journal.

[367]  G. Pellegrini,et al.  Plasminogen Activator Inhibitor Type 1 Is Increased in the Arterial Wall of Type II Diabetic Subjects , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[368]  P. Serruys,et al.  Clinical and Economic Impact of Diabetes Mellitus on Percutaneous and Surgical Treatment of Multivessel Coronary Disease Patients , 2001 .

[369]  P. Serruys,et al.  Clinical and Economic Impact of Diabetes Mellitus on Percutaneous and Surgical Treatment of Multivessel Coronary Disease Patients: Insights From the Arterial Revascularization Therapy Study (ARTS) Trial , 2001, Circulation.

[370]  W C Willett,et al.  The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. , 2001, Archives of internal medicine.

[371]  J. Manson,et al.  C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.

[372]  R. D'Agostino,et al.  Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. , 2001, JAMA.

[373]  Mark Hargreaves,et al.  Adrenaline increases skeletal muscle glycogenolysis, pyruvate dehydrogenase activation and carbohydrate oxidation during moderate exercise in humans , 2001, The Journal of physiology.

[374]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[375]  W. Hiatt,et al.  Medical treatment of peripheral arterial disease and claudication. , 2001, The New England journal of medicine.

[376]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[377]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[378]  F. Game,et al.  Coronary heart disease risk assessment in diabetes mellitus–‐a comparison of PROCAM and Framingham risk assessment functions , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[379]  A. Cowley,et al.  Beneficial haemodynamic effects of insulin in chronic heart failure , 2001, Heart.

[380]  M. Sclavo [Physical activity and risk for cardiovascular events in diabetic women]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[381]  T. Bowker,et al.  Difference in the mortality of the CABRI diabetic and nondiabetic populations and its relation to coronary artery disease and the revascularization mode. , 2001, The American journal of cardiology.

[382]  P. Whelton,et al.  Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. , 2001, Archives of internal medicine.

[383]  L. Groop,et al.  Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.

[384]  Y Li,et al.  Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus. , 2001, American journal of physiology. Heart and circulatory physiology.

[385]  L. Suzuki,et al.  Diabetes accelerates smooth muscle accumulation in lesions of atherosclerosis: lack of direct growth-promoting effects of high glucose levels. , 2001, Diabetes.

[386]  D. Wennberg,et al.  Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective study. Northern New England Cardiovascular Disease Study Group. , 2001, Journal of the American College of Cardiology.

[387]  L. Wilhelmsen,et al.  Heart failure in the general population of men--morbidity, risk factors and prognosis. , 2001, Journal of internal medicine.

[388]  C. Bauters,et al.  Patency of Percutaneous Transluminal Coronary Angioplasty Sites at 6-Month Angiographic Follow-Up: A Key Determinant of Survival in Diabetics After Coronary Balloon Angioplasty , 2001, Circulation.

[389]  M. Wallander,et al.  Incidence of newly diagnosed heart failure in UK general practice , 2001, European journal of heart failure.

[390]  H. Adachi,et al.  Is insulin resistance or diabetes mellitus associated with stroke? An 18-year follow-up study. , 2001, Diabetes research and clinical practice.

[391]  L. Landsberg Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why) , 2001, Journal of hypertension.

[392]  S. Arikian,et al.  THE COST‐EFFECTIVENESS OF DOXAZOSIN FOR THE TREATMENT OF HYPERTENSION IN TYPE II DIABETIC PATIENTS IN THE UK AND ITALY , 2001, International journal of clinical practice.

[393]  C. Loria,et al.  Subclinical states of glucose intolerance and risk of death in the U.S. , 2001, Diabetes care.

[394]  T. Münzel,et al.  Mechanisms Underlying Endothelial Dysfunction in Diabetes Mellitus , 2001, Circulation research.

[395]  G. Pogátsa Metabolic energy metabolism in diabetes: therapeutic implications. , 2001, Coronary artery disease.

[396]  A. Pfeiffer,et al.  Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro , 2001, Diabetologia.

[397]  K. Borch-Johnsen The new classification of diabetes mellitus and IGT: a critical approach. , 2001, Experimental and clinical endocrinology & diabetes.

[398]  A. Malhotra,et al.  Stress-induced hyperglycemia. , 2001, Critical care clinics.

[399]  David R. Wood,et al.  Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. , 2001, European heart journal.

[400]  I. Palacios,et al.  Argentine Randomized Study: Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators. , 2001, Journal of the American College of Cardiology.

[401]  C. Bogardus,et al.  Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. , 2001, Diabetes care.

[402]  E. Feskens,et al.  Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. , 2001, Archives of internal medicine.

[403]  P A Wolf,et al.  Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. , 2001, Circulation.

[404]  T. Lüscher,et al.  Enhanced Peroxynitrite Formation Is Associated with Vascular Aging , 2000, The Journal of experimental medicine.

[405]  John Wikstrand,et al.  Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients with Heart Failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) , 2000 .

[406]  P. Poole‐Wilson,et al.  Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. , 2000, European heart journal.

[407]  M. Hanefeld,et al.  Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. , 2000, Diabetes care.

[408]  J. Meigs,et al.  Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. , 2000, American journal of epidemiology.

[409]  J. W. Box,et al.  Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb Study , 2000 .

[410]  C. Östenson,et al.  Direct medical costs for patients with type 2 diabetes in Sweden , 2000, Journal of internal medicine.

[411]  T. Hedner,et al.  Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension–2 , 2000, Journal of hypertension.

[412]  O. Schnell,et al.  A new look at the heart in diabetes mellitus: from ailing to failing , 2000, Diabetologia.

[413]  J. Tuomilehto,et al.  Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. , 2000, Diabetes care.

[414]  H. Ginsberg,et al.  The Insulin Resistance Syndrome: Impact on Lipoprotein Metabolism and Atherothrombosis , 2000, Journal of cardiovascular risk.

[415]  M. Engelgau,et al.  Screening for type 2 diabetes. , 2000, Diabetes care.

[416]  J. Ottervanger,et al.  Long-term benefit of primary angioplasty compared to thrombolytic therapy for acute myocardial infarction. , 2000, European heart journal.

[417]  S. Yusuf,et al.  Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry , 2000, Circulation.

[418]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[419]  H. Yki-Järvinen Comparison of insulin regimens for patients with type 2 diabetes , 2000 .

[420]  Jagmeet P. Singh,et al.  Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). , 2000, The American journal of cardiology.

[421]  Thomas Hedner,et al.  Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study , 2000, The Lancet.

[422]  S. Haffner,et al.  Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). , 2000, Circulation.

[423]  S. Schmidt-Schweda,et al.  First clinical trial with etomoxir in patients with chronic congestive heart failure. , 2000, Clinical science.

[424]  W. Rand,et al.  Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy. , 2000, American heart journal.

[425]  K. Feingold,et al.  Infection and inflammation-induced proatherogenic changes of lipoproteins. , 2000, The Journal of infectious diseases.

[426]  Bertram Pitt,et al.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.

[427]  R. Heethaar,et al.  Glucose tolerance and other determinants of cardiovascular autonomic function: the Hoorn Study , 2000, Diabetologia.

[428]  Steven Blair,et al.  Low Cardiorespiratory Fitness and Physical Inactivity as Predictors of Mortality in Men with Type 2 Diabetes , 2000, Annals of Internal Medicine.

[429]  Y. Kaneda,et al.  Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage , 2000, Nature.

[430]  Bari Investigators Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. , 2000, Journal of the American College of Cardiology.

[431]  Deepak L. Bhatt,et al.  Abciximab reduces mortality in diabetics following percutaneous coronary intervention. , 2000, Journal of the American College of Cardiology.

[432]  R Dietz,et al.  Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. , 2000, JAMA.

[433]  H. Gerstein,et al.  Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview , 2000, The Lancet.

[434]  B. Howard,et al.  LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[435]  S. Nuttall,et al.  beta Blockade after myocardial infarction. Beta blockers have key role in reducing morbidity and mortality after infarction. , 2000, BMJ.

[436]  A. Rovlias,et al.  The influence of hyperglycemia on neurological outcome in patients with severe head injury. , 2000, Neurosurgery.

[437]  M. Laakso,et al.  Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with Type II diabetes , 2000, Diabetologia.

[438]  W. Koenig,et al.  The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? , 2000, Diabetologia.

[439]  S. Juvela,et al.  Risk factors for multiple intracranial aneurysms. , 2000, Stroke.

[440]  J. Staessen,et al.  Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. , 2000, Archives of internal medicine.

[441]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.

[442]  S. Yusuf,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[443]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[444]  L. Deckelbaum,et al.  Effect of plasma insulin level on myocardial blood flow and its mechanism of action. , 2000, The American journal of cardiology.

[445]  S. Yusuf,et al.  Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53. , 2000 .

[446]  M. Glanz,et al.  The Sharer , 2000, Annals of Internal Medicine.

[447]  A. Whittemore Presidential address: a team for the 21st century: the vascular center. , 2000, Journal of vascular surgery.

[448]  R. Rutherford,et al.  Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). , 2000, Journal of vascular surgery.

[449]  E. Standl,et al.  Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. , 2000, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[450]  HOMAS,et al.  The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .

[451]  Ames,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[452]  Illiam,et al.  THE EFFECT OF NISOLDIPINE AS COMPARED WITH ENALAPRIL ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES AND HYPERTENSION , 2000 .

[453]  Tseng Chin-Hsiao The Costs of Diabetes , 2000 .

[454]  Y. Suematsu,et al.  Predictive risk factors for delayed extubation in patients undergoing coronary artery bypass grafting , 2000, Heart and Vessels.

[455]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[456]  S. Haffner,et al.  Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. , 1999, Archives of internal medicine.

[457]  X. Jouven,et al.  Diabetes as a risk factor for sudden death , 1999, The Lancet.

[458]  J. Halperin,et al.  Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). , 1999, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[459]  L. Rydén,et al.  Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients. , 1999, Diabetes care.

[460]  M. Chaney,et al.  Attempting to maintain normoglycemia during cardiopulmonary bypass with insulin may initiate postoperative hypoglycemia. , 1999, Anesthesia and analgesia.

[461]  S. Milstien,et al.  Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. , 1999, Biochemical and biophysical research communications.

[462]  B. Jönsson,et al.  The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial , 1999, Diabetologia.

[463]  C. Bogardus,et al.  The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. , 1999, The Journal of clinical investigation.

[464]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[465]  G. Habib,et al.  Silent myocardial ischemia in patients with diabetes: who to screen. , 1999, Diabetes care.

[466]  James W. Anderson,et al.  Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may Be due to the abnormal composition of HDL. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[467]  P. Savage,et al.  Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria , 1999, The Lancet.

[468]  E. Feskens,et al.  Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria , 1999, The Lancet.

[469]  J. Shaw,et al.  Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality , 1999, Diabetologia.

[470]  C. Bauters,et al.  Restenosis, late vessel occlusion and left ventricular function six months after balloon angioplasty in diabetic patients. , 1999, Journal of the American College of Cardiology.

[471]  K. Yano,et al.  Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program. , 1999, Diabetes care.

[472]  A. Folsom,et al.  Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. , 1999, Diabetes care.

[473]  S. Lévy,et al.  Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. , 1999, Circulation.

[474]  R. Holman,et al.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.

[475]  A Sekikawa,et al.  Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. , 1999, Diabetes care.

[476]  L. Rydén,et al.  Diabetes mellitus and congestive heart failure. Further knowledge needed. , 1999, European heart journal.

[477]  R McBride,et al.  Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. , 1999, Stroke.

[478]  H Wedel,et al.  Infarction : Long-Term Results From the Diabetes and Insulin-Glucose Infusion Conventionally Treated Patients With Diabetes Mellitus and Acute Myocardial Glycometabolic State at Admission : Important Risk Marker of Mortality in , 1999 .

[479]  R. Holman,et al.  Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29. , 1999, Archives of internal medicine.

[480]  Gerardo Heiss,et al.  Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study , 1999, The Lancet.

[481]  S. Grundy Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. , 1999, The American journal of cardiology.

[482]  Eber,et al.  Effects of intensified lifestyle modification on the need for further revascularization after coronary angioplasty , 1999, European journal of clinical investigation.

[483]  M. Laakso,et al.  Hyperglycemia and cardiovascular disease in type 2 diabetes. , 1999, Diabetes.

[484]  A. Vinik Diagnosis and management of diabetic neuropathy. , 1999, Clinics in geriatric medicine.

[485]  B. Balkau,et al.  Comment on the provisional report from the WHO consultation , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[486]  M. Harris,et al.  Diabetes and decline in heart disease mortality in US adults. , 1999, JAMA.

[487]  E. Jones,et al.  Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. , 1999, The Annals of thoracic surgery.

[488]  J. Hokanson,et al.  Dyslipidemia of central obesity and insulin resistance. , 1999, Diabetes Care.

[489]  A. Manto,et al.  Blunted erythropoietin response to anemia in type 1 diabetic patients. , 1999, Diabetes care.

[490]  J. Ottervanger,et al.  Primary angioplasty compared with thrombolysis in acute myocardial infarction in diabetic patients. , 1999, Diabetes care.

[491]  J. Sowers,et al.  Diabetes and cardiovascular disease. , 1999, Diabetes care.

[492]  E. Topol,et al.  The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics. , 1999, Journal of the American College of Cardiology.

[493]  C. Bulpitt,et al.  Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension , 1999 .

[494]  F. Zannad,et al.  Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. Epidémiologie de l'Insuffisance Cardiaque Avancée en Lorraine. , 1999, Journal of the American College of Cardiology.

[495]  A Hofman,et al.  Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. , 1999, European heart journal.

[496]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[497]  R. Califf,et al.  Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Aypass Angioplasty Revascularization Investigation (BARI). , 1999, Circulation.

[498]  S. Yusuf,et al.  The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. , 1999, Diabetes care.

[499]  CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[500]  I. U. Haq,et al.  Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men , 1999, Heart.

[501]  武井泉,et al.  United Kingdom Prospective Diabetes Study (UKPDS) , 1999 .

[502]  W. Herman,et al.  Renal assessment practices and the effect of nurse case management of health maintenance organization patients with diabetes. , 1999, Diabetes care.

[503]  B. Vessby,et al.  Improved glycemic control and lipid profile and normalized fibrinolytic activity on a low-glycemic index diet in type 2 diabetic patients. , 1999, Diabetes care.

[504]  F. Tediosi,et al.  Costs of diabetes. A methodological analysis of the literature. , 1999, PharmacoEconomics.

[505]  J. Tuomilehto,et al.  Consequences of the new diagnostic criteria for diabetes in older men and women. DECODE Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe). , 1999, Diabetes care.

[506]  O. Ljungqvist,et al.  Insulin resistance: a marker of surgical stress. , 1999, Current opinion in clinical nutrition and metabolic care.

[507]  N Freemantle,et al.  beta Blockade after myocardial infarction: systematic review and meta regression analysis. , 1999, BMJ.

[508]  B. Jönsson,et al.  Diabetes: the cost of illness in Sweden , 1998, Journal of internal medicine.

[509]  P. Stacpoole,et al.  Effects of dichloroacetate in patients with congestive heart failure , 1998, Clinical cardiology.

[510]  M. Hadamitzky,et al.  Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. , 1998, Journal of the American College of Cardiology.

[511]  G. Keresztury,et al.  Atherosclerosis in amputated legs of patients with and without diabetes mellitus. , 1998, International angiology : a journal of the International Union of Angiology.

[512]  L. Piegas,et al.  Metabolic Modulation of Acute Myocardial Infarction The ECLA Glucose-Insulin-Potassium Pilot Trial , 1998 .

[513]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[514]  S. Pocock,et al.  Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting , 1998, The Lancet.

[515]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[516]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[517]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[518]  H. King,et al.  Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections , 1998, Diabetes Care.

[519]  A. Schmidt,et al.  Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.

[520]  B. Howard,et al.  Lowering fatty acids potentiates acute insulin response in first degree relatives of people with Type II diabetes , 1998, Diabetologia.

[521]  S. Gottlieb,et al.  Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. , 1998, The New England journal of medicine.

[522]  H. Lithell,et al.  Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data , 1998 .

[523]  E. Barrett-Connor,et al.  Isolated Postchallenge Hyperglycemia and the Risk of Fatal Cardiovascular Disease in Older Women and Men: The Rancho Bernardo Study , 1998, Diabetes Care.

[524]  R. D'Agostino,et al.  Sudden coronary death in women. , 1998, American heart journal.

[525]  M. Laakso,et al.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.

[526]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[527]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[528]  M. Simoons,et al.  Unstable angina: good long-term outcome after a complicated early course. , 1998, Journal of the American College of Cardiology.

[529]  J. Tuomilehto,et al.  Incidence of cardiovascular disease in Type 1 (insulin-dependent) diabetic subjects with and without diabetic nephropathy in Finland , 1998, Diabetologia.

[530]  Farris K. Timimi,et al.  Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. , 1998, Circulation.

[531]  R. Campbell,et al.  Management Strategies for a Better Outcome in Unstable Coronary Artery Disease , 1998, Clinical cardiology.

[532]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[533]  K. Flegal,et al.  Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in U.S. Adults: The Third National Health and Nutrition Examination Survey, 1988–1994 , 1998, Diabetes Care.

[534]  M. Pahor,et al.  Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients With Hypertension and NIDDM , 1998, Diabetes Care.

[535]  R. Holman,et al.  Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23) , 1998, BMJ.

[536]  D. Holmes,et al.  Lessons from the Pooled Outcome of the PAMI, ZWOLLE and Mayo Clinic Randomized Trials of Primary Angioplasty Versus Thrombolytic Therapy of Acute Myocardial Infarction. , 1998, The Journal of invasive cardiology.

[537]  Arno W. Hoes,et al.  Peripheral arterial disease in the elderly: The Rotterdam Study. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[538]  T. Lüscher,et al.  Atherosclerosis and the two faces of endothelial nitric oxide synthase. , 1998, Circulation.

[539]  O'Neill Ww Multivessel balloon angioplasty should be abandoned in diabetic patients , 1998 .

[540]  W. O’Neill Multivessel balloon angioplasty should be abandoned in diabetic patients! , 1998, Journal of the American College of Cardiology.

[541]  Z. Naito,et al.  Immunohistochemical and morphometric evaluations of coronary atherosclerotic plaques associated with myocardial infarction and diabetes mellitus. , 1998, Journal of atherosclerosis and thrombosis.

[542]  R F Anda,et al.  Impact of multiple risk factor profiles on determining cardiovascular disease risk. , 1998, Preventive medicine.

[543]  T. Meinertz,et al.  Intravenous coronary angiography with synchrotron radiation: experience in 195 patients , 1998 .

[544]  P. Whelton,et al.  Risk of End-stage Renal Disease in Diabetes Mellitus: A Prospective Cohort Study of Men Screened for MRFIT , 1997 .

[545]  P. Whelton,et al.  Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. , 1997, JAMA.

[546]  A. Maggioni,et al.  Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. , 1997, Circulation.

[547]  M. Omata,et al.  Reduced myocardial flow reserve in non-insulin-dependent diabetes mellitus. , 1997, Journal of the American College of Cardiology.

[548]  E. Braunwald Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. , 1997, The New England journal of medicine.

[549]  J. Colwell Aspirin Therapy in Diabetes , 1997, Diabetes Care.

[550]  R. Califf,et al.  Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. , 1997, Circulation.

[551]  L H Kuller,et al.  Incidence of and risk factors for atrial fibrillation in older adults. , 1997, Circulation.

[552]  M W Knuiman,et al.  Prediction of coronary heart disease mortality in Busselton, Western Australia: an evaluation of the Framingham, national health epidemiologic follow up study, and WHO ERICA risk scores. , 1997, Journal of epidemiology and community health.

[553]  T. B. Investigators,et al.  Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) , 1997, Circulation.

[554]  A. Algra,et al.  Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke , 1997, Journal of the Neurological Sciences.

[555]  J. Evans,et al.  ACE Inhibitor Use Is Associated With Hospitalization for Severe Hypoglycemia in Patients With Diabetes , 1997, Diabetes Care.

[556]  K. Beatt,et al.  Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. , 1997, Circulation.

[557]  S. Anker,et al.  Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. , 1997, Journal of the American College of Cardiology.

[558]  M. Laakso,et al.  Dyslipidemia and Hyperglycemia Predict Coronary Heart Disease Events in Middle-Aged Patients With NIDDM , 1997, Diabetes.

[559]  Strokepreventioninatrialfibri The stroke prevention in atrial fibrillation III study: rationale, design, and patient features. , 1997, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[560]  D. Singer,et al.  The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is … or is it? , 1997, The Lancet.

[561]  R. Califf,et al.  Influence of Diabetes Mellitus on Clinical Outcome in the Thrombolytic Era of Acute Myocardial Infarction , 1997 .

[562]  G. Paolisso,et al.  Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. , 1997, Diabetes & metabolism.

[563]  R. Califf,et al.  Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model. , 1997, American heart journal.

[564]  K. Malmberg Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus , 1997, BMJ.

[565]  Terje R Pedersen,et al.  Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.

[566]  B. Howard,et al.  Effects of Diet and Exercise in Preventing NIDDM in People With Impaired Glucose Tolerance: The Da Qing IGT and Diabetes Study , 1997, Diabetes Care.

[567]  L. Rydén,et al.  Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study. , 1997, Cardiovascular research.

[568]  A. Dyer,et al.  Diabetes, Asymptomatic Hyperglycemia, and 22-Year Mortality in Black and White Men: The Chicago Heart Association Detection Project in Industry Study , 1997, Diabetes Care.

[569]  T. Kuzuya,et al.  Classification of Diabetes on the Basis of Etiologies Versus Degree of Insulin Deficiency , 1997, Diabetes Care.

[570]  G. Reaven Banting lecture 1988 , 1997 .

[571]  S. Neugebauer,et al.  Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention. , 1997, Drugs.

[572]  C. Forbes,et al.  EUROPEAN STROKE PREVENTION STUDY 2: DIPYRIDAMOLE AND ACETYLSALICYLIC ACID IN THE SECONDARY PREVENTION OF STROKE , 1997, International journal of clinical practice.

[573]  S. Haffner,et al.  Are risk factors for conversion to NIDDM similar in high and low risk populations? , 1997, Diabetologia.

[574]  B. Davis,et al.  Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. , 1996, JAMA.

[575]  Cindy Farquhar,et al.  3 The Cochrane Library , 1996 .

[576]  D. C. Warner,et al.  Costs of diabetes in Texas, 1992 , 1996, Diabetes Care.

[577]  R. Califf,et al.  Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. , 1996, Journal of the American College of Cardiology.

[578]  R. Holle,et al.  Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project , 1996, Diabetologia.

[579]  M. Hanefeld,et al.  Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up , 1996, Diabetologia.

[580]  M. Laakso,et al.  Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. , 1996, Stroke.

[581]  J S Beckman,et al.  Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. , 1996, The American journal of physiology.

[582]  D. Faxon,et al.  Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. , 1996, Circulation.

[583]  James T. Willerson,et al.  Appointment of New Associate Editor for Circulation , 1996 .

[584]  T. Orchard The impact of gender and general risk factors on the occurrence of atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. , 1996, Annals of medicine.

[585]  L. Niskanen,et al.  Autonomic neuropathy predicts the development of stroke in patients with non-insulin-dependent diabetes mellitus. , 1996, Stroke.

[586]  Robert L. Frye,et al.  Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. , 1996, The New England journal of medicine.

[587]  M. Muggeo,et al.  Cardiovascular Disease and Its Risk Factors in IDDM in Europe , 1996, Diabetes Care.

[588]  U. Goldbourt,et al.  Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group. , 1996, The American journal of cardiology.

[589]  H. Barnhart,et al.  Effectiveness of revascularization in the Emory angioplasty versus surgery trial. A randomized comparison of coronary angioplasty with bypass surgery. , 1996, Circulation.

[590]  M. Laakso,et al.  Structure and Costs of Health Care of Diabetic Patients in Finland , 1996, Diabetes Care.

[591]  G. Leese,et al.  The Management of Hypertension in Diabetes: with Special Reference to Diabetic Kidney Disease , 1996, Diabetic medicine : a journal of the British Diabetic Association.

[592]  R. Wolfe,et al.  TNF directly stimulates glucose uptake and leucine oxidation and inhibits FFA flux in conscious dogs. , 1996, The American journal of physiology.

[593]  J. Hokanson,et al.  Plasma Triglyceride Level is a Risk Factor for Cardiovascular Disease Independent of High-Density Lipoprotein Cholesterol Level: A Metaanalysis of Population-Based Prospective Studies , 1996, Journal of cardiovascular risk.

[594]  J. Sturis,et al.  Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. , 1996, The New England journal of medicine.

[595]  M. Creager,et al.  -.____----.---_-Impaired Nitric Oxide-Mediated Vasodilation in Patients With Non-Insulin-Dependent Diabetes Mellitw , 2016 .

[596]  E. Vartiainen,et al.  Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population. , 1996, Stroke.

[597]  G. Sundkvist,et al.  Capillary Blood on Filter Paper for Determination of HbA1c by Ion Exchange Chromatography , 1996, Diabetes Care.

[598]  S. Fava,et al.  The Prognostic Value of Blood Glucose in Diabetic Patients with Acute Myocardial Infarction , 1996, Diabetic medicine : a journal of the British Diabetic Association.

[599]  D. Clement A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[600]  J. Fuller,et al.  International variations in cardiovascular mortality associated with diabetes mellitus: the WHO Multinational Study of Vascular Disease in Diabetes. , 1996, Annals of medicine.

[601]  M. Laakso,et al.  Epidemiological evidence for the association of hyperglycaemia and atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. , 1996, Annals of medicine.

[602]  M. Laakso,et al.  Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. , 1996, Stroke.

[603]  Farris K. Timimi,et al.  Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. , 1996, The Journal of clinical investigation.

[604]  A. Gray,et al.  The Cost of Insulin‐dependent Diabetes Mellitus (IDDM) in England and Wales , 1995, Diabetic medicine : a journal of the British Diabetic Association.

[605]  R. Jones,et al.  Mediastinitis After Coronary Artery Bypass Graft Surgery: Risk Factors and Long‐Term Survival , 1995, Circulation.

[606]  A. Hamsten,et al.  Insulin, intact and split proinsulin, and coronary artery disease in young men. , 1995, Circulation.

[607]  K. Kario,et al.  Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[608]  M. Pirisi,et al.  Hyperglycemia-Induced Thrombin Formation in Diabetes: The Possible Role of Oxidative Stress , 1995, Diabetes.

[609]  J. Deckers,et al.  Efficacy of long-term anticoagulant treatment in subgroups of patients after myocardial infarction. , 1995, British heart journal.

[610]  J Herlitz,et al.  Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. , 1995, Journal of the American College of Cardiology.

[611]  G. Dailey,et al.  Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. , 1995, JAMA.

[612]  G. Thorgeirsson,et al.  Glucose tolerance and blood pressure in a population-based cohort study of males and females: the Reykjavik Study , 1995, Journal of hypertension.

[613]  D. Brater,et al.  Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure , 1995, Clinical pharmacology and therapeutics.

[614]  A. Shehadeh,et al.  Cardiac consequences of diabetes mellitus , 1995, Clinical cardiology.

[615]  K. Yano,et al.  Sudden death, impaired glucose tolerance, and diabetes in Japanese American men. , 1995, Circulation.

[616]  R. Herings,et al.  Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme , 1995, The Lancet.

[617]  M. Cybulsky,et al.  Advanced Glycation Endproducts Promote Adhesion Molecule (VCAM-1, ICAM-1) Expression and Atheroma Formation in Normal Rabbits , 1995, Molecular medicine.

[618]  E. Araki,et al.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. , 1995, Diabetes research and clinical practice.

[619]  K. Narayan,et al.  Preventing Non-Insulin-Dependent Diabetes , 1995, Diabetes.

[620]  F A Mathewson,et al.  The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. , 1995, The American journal of medicine.

[621]  E. Lengerich,et al.  The burden of diabetes in North Carolina. , 1995, North Carolina medical journal.

[622]  M. Schroll,et al.  Stroke incidence, case fatality, and mortality in the WHO MONICA project. World Health Organization Monitoring Trends and Determinants in Cardiovascular Disease. , 1995, Stroke.

[623]  R. Hamman,et al.  Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. , 1995, Circulation.

[624]  W. Weintraub,et al.  Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. , 1995, Circulation.

[625]  E. Vartiainen,et al.  The North Karelia project : 20 year results and experiences , 1995 .

[626]  J. Simoneau,et al.  Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus. , 1994, The Journal of clinical investigation.

[627]  J. Gardin,et al.  Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). , 1994, The American journal of cardiology.

[628]  I. Hirsch,et al.  Reduced Plasma Peroxyl Radical Trapping Capacity and Increased Susceptibility of LDL to Oxidation In Poorly Controlled IDDM , 1994, Diabetes.

[629]  C. Fry,et al.  Science of urinary incontinence Report of a Meeting of Physicians and Scientists, University College London , 1994, The Lancet.

[630]  J. Mecklin,et al.  The International Collaborative Group on HNPCC. , 1994, Anticancer research.

[631]  H. Tunstall-Pedoe,et al.  Myocardial Infarction and Coronary Deaths in the World Health Organization MONICA Project: Registration Procedures, Event Rates, and Case‐Fatality Rates in 38 Populations From 21 Countries in Four Continents , 1994, Circulation.

[632]  J. Stengård,et al.  Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[633]  Chalmers Tc,et al.  A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. , 1994, International angiology : a journal of the International Union of Angiology.

[634]  M. Laakso,et al.  Non‐Insulin‐Dependent Diabetes and Its Metabolic Control Are Important Predictors of Stroke in Elderly Subjects , 1994, Stroke.

[635]  B. Davis,et al.  Uniformity of captopril benefit in the SAVE study : subgroup analysis , 1994 .

[636]  D N Mendelson,et al.  Health care expenditures for people with diabetes mellitus, 1992. , 1994, The Journal of clinical endocrinology and metabolism.

[637]  A. Hedley,et al.  A prospective population based study of gender differential in mortality from cardiovascular disease and "all causes" in asymptomatic hyperglycaemics. , 1994, Journal of clinical epidemiology.

[638]  D. Levy,et al.  Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. , 1994, JAMA.

[639]  A. Marette,et al.  Regulation of expression of glucose transporters by glucose: a review of studies in vivo and in cell cultures , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[640]  T. Chalmers,et al.  A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. , 1994, International angiology : a journal of the International Union of Angiology.

[641]  J. Bassand GUSTO (Global Utilization of Streptokinase and Tissue plasminogen activator in Occluded arteries): logic wins at last. , 1994, European heart journal.

[642]  Johan Herlitz,et al.  Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .

[643]  G. Murray,et al.  Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators , 1993 .

[644]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[645]  Å. Lernmark,et al.  β-Cell Function in Relation to Islet Cell Antibodies During the First 3 Yr After Clinical Diagnosis of Diabetes in Type II Diabetic Patients , 1993, Diabetes Care.

[646]  L. Poller,et al.  Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. , 1993, The New England journal of medicine.

[647]  J. Neaton,et al.  Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.

[648]  M. Rewers,et al.  Global Estimates for Prevalence of Diabetes Mellitus and Impaired Glucose Tolerance in Adults , 1993, Diabetes Care.

[649]  Å. Lernmark,et al.  Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. , 1993, Diabetes care.

[650]  F. A. Gries,et al.  The Epidemiology of Diabetic Neuropathy , 1993 .

[651]  T. Songer The economic costs of NIDDM. , 1992, Diabetes/metabolism reviews.

[652]  S M Nazarian,et al.  Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. , 1992, The New England journal of medicine.

[653]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[654]  S. Haffner,et al.  Prospective analysis of the insulin-resistance syndrome (syndrome X). , 1992, Diabetes.

[655]  S. Yusuf,et al.  Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. , 1992, Circulation.

[656]  S. Yusuf,et al.  Effects of the Angiotensin Converting Enzyme Inhibitor Enalapril on the Long‐term: Progression of Left Ventricular Dysfunction in Patients With Heart Failure , 1992, Circulation.

[657]  J. Huttunen,et al.  Coronary Heart Disease Incidence in NIDDM Patients In The Helsinki Heart Study , 1992, Diabetes Care.

[658]  M. Laakso,et al.  European Stroke Prevention Study: Effectiveness of Antiplatelet Therapy in Diabetic Patients in Secondary Prevention of Stroke , 1992, Stroke.

[659]  A. Swai,et al.  Must diabetes be a fatal disease in Africa? Study of costs of treatment. , 1992, BMJ.

[660]  J. Remes,et al.  Incidence of heart failure in eastern Finland: a population-based surveillance study. , 1992, European heart journal.

[661]  J. Hopper,et al.  Stroke topography and outcome in relation to hyperglycaemia and diabetes. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[662]  J. Salmerón,et al.  Diabetes in Mexico--a serious and growing problem. , 1992, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.

[663]  C H Lang,et al.  Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. , 1992, Endocrinology.

[664]  M. Hill,et al.  Altered transcriptional regulation of phosphoenolpyruvate carboxykinase in rats following endotoxin treatment. , 1991, The Journal of clinical investigation.

[665]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[666]  M. Laakso,et al.  The European Stroke Prevention Study , 1991, Neurology.

[667]  M Gent,et al.  Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. , 1991, Journal of the American College of Cardiology.

[668]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[669]  I. O'Brien,et al.  The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. , 1991, The Quarterly journal of medicine.

[670]  L Heinemann,et al.  Prevalence of renal artery stenosis in diabetes mellitus — an autopsy study , 1991, Journal of internal medicine.

[671]  R. Cohen,et al.  Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. , 1991, The Journal of clinical investigation.

[672]  R. Narayan,et al.  The influence of diabetes mellitus on outcome from subarachnoid hemorrhage. , 1991, Diabetes research.

[673]  E. Barrett-Connor,et al.  Sex differences in fasting glycemia as a risk factor for ischemic heart disease death. , 1991, American journal of epidemiology.

[674]  V. Salomaa,et al.  Glucose tolerance and blood pressure: long term follow up in middle aged men. , 1991, BMJ.

[675]  R B D'Agostino,et al.  Probability of stroke: a risk profile from the Framingham Study. , 1991, Stroke.

[676]  E. Barrett-Connor,et al.  Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. , 1991, JAMA.

[677]  Bernard Rosner,et al.  The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. , 1990, The New England journal of medicine.

[678]  P. Wolf,et al.  Black-white differences in stroke incidence in a national sample. The contribution of hypertension and diabetes mellitus. , 1990, JAMA.

[679]  A. Alavi,et al.  Relation of hyperglycemia early in ischemic brain infarction to cerebral anatomy, metabolism, and clinical outcome , 1990, Annals of neurology.

[680]  Paul M. Vanhoutte,et al.  The Endothelium: Modulator of Cardiovascular Function , 1990 .

[681]  J. Pomposelli,et al.  Effect of interleukin-1 and tumor necrosis factor/cachectin on glucose turnover in the rat. , 1990, Metabolism: clinical and experimental.

[682]  R. Loewenson,et al.  Influence of Pancreas Transplantation on Cardiorespiratory Reflexes, Nerve Conduction, and Mortality in Diabetes Mellitus , 1990, Diabetes.

[683]  N. Kouchoukos,et al.  Risks of bilateral internal mammary artery bypass grafting. , 1990, The Annals of thoracic surgery.

[684]  E. Gilpin,et al.  Diabetic patients and beta-blockers after acute myocardial infarction. , 1990, European heart journal.

[685]  J. Longhurst Coronary arteriolar vasoconstriction in myocardial ischaemia: reflexes, sympathetic nervous system, catecholamines. , 1990, European heart journal.

[686]  M. Hanefeld,et al.  Das Metabolische Syndrom , 2006 .

[687]  G A Colditz,et al.  The economic costs of non-insulin-dependent diabetes mellitus. , 1989, JAMA.

[688]  C. Furberg,et al.  Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. , 1989, BMJ.

[689]  T. Blanck,et al.  VOLATILE ANESTHETIC DEPRESSION OF CALCIUM CHANNELS IN BRAIN MEMBRANES , 1989 .

[690]  J. Herman,et al.  Diabetes and hypertension. Blood pressure in clinical diabetic patients and a control population. , 1989, Archives of internal medicine.

[691]  V. Katch,et al.  The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. , 1989, The New England journal of medicine.

[692]  C. Lan,et al.  Prevalence of stroke in Taiwan. , 1989, Stroke.

[693]  L. Rydén,et al.  Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies. , 1989, European heart journal.

[694]  Mckendry Jb Direct costs of diabetes care: a survey in Ottawa, Ontario 1986. , 1989 .

[695]  Erzo F. P. Luttmer,et al.  The Cost of Diabetes , 1989, Diabetic medicine : a journal of the British Diabetic Association.

[696]  Palle Petersen,et al.  PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION The Copenhagen AFASAK Study , 1989, The Lancet.

[697]  J. Kampine,et al.  Increased intraoperative cardiovascular morbidity in diabetics with autonomic neuropathy. , 1987, Anesthesiology.

[698]  J. Tuomilehto,et al.  WHO MONICA Project: assessing CHD mortality and morbidity. , 1989, International journal of epidemiology.

[699]  J. McKendry Direct costs of diabetes care: a survey in Ottawa, Ontario 1986. , 1989, Canadian journal of public health = Revue canadienne de sante publique.

[700]  G. Reaven Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[701]  E. Barrett-Connor,et al.  Diabetes mellitus: an independent risk factor for stroke? , 1988, American journal of epidemiology.

[702]  E. Kraegen,et al.  Physiological Importance of Deficiency in Early Prandial Insulin Secretion in Non-Insulin-Dependent Diabetes , 1988, Diabetes.

[703]  L. Rydén,et al.  Myocardial infarction in patients with diabetes mellitus. , 1988, European heart journal.

[704]  D. Faxon,et al.  Percutaneous transluminal coronary angioplasty in 1985-1986 and 1977-1981. The National Heart, Lung, and Blood Institute Registry. , 1988, The New England journal of medicine.

[705]  E. Eschwège,et al.  The cost of diabetes in France. , 1988, Health policy.

[706]  P. Wolf,et al.  Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. , 1987, Archives of internal medicine.

[707]  G. Rose,et al.  RISK OF STROKE IN NON-RHEUMATIC ATRIAL FIBRILLATION , 1987, The Lancet.

[708]  J. P. O’Hare,et al.  The prevalence of autonomic neuropathy in insulin-dependent diabetes mellitus: a controlled study based on heart rate variability. , 1986, The Quarterly journal of medicine.

[709]  N. Cox,et al.  Diabetes mellitus and early mortality from stroke , 1985, British medical journal.

[710]  G. Clagett Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease: A prospective double-blind arteriographically controlled trial , 1985 .

[711]  S. Lillioja,et al.  Relationship between degree of obesity and in vivo insulin action in man. , 1985, The American journal of physiology.

[712]  M. Laakso,et al.  Age of Onset and Type of Diabetes , 1985, Diabetes Care.

[713]  H. Adams,et al.  Prevalence of diabetes mellitus among patients with subarachnoid hemorrhage. , 1984, Archives of neurology.

[714]  J. Halter,et al.  Pathophysiology of Insulin Secretion in Non-insulin-dependent Diabetes Mellitus , 1984, Diabetes Care.

[715]  L. Sjöström,et al.  Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. , 1983, The Journal of clinical investigation.

[716]  L. Elveback,et al.  Transient ischemic attack and stroke in a community-based diabetic cohort. , 1983, Mayo Clinic proceedings.

[717]  B. Jönsson Diabetes--the cost of illness and the cost of control. An estimate for Sweden 1978. , 1983, Acta medica Scandinavica. Supplementum.

[718]  D. Porte,et al.  Glycosylated Hemoglobin and Fasting Plasma Glucose in the Assessment of Outpatient Glycemic Control in NIDDM , 1982, Diabetes Care.

[719]  A. Kissebah,et al.  Relation of body fat distribution to metabolic complications of obesity. , 1982, The Journal of clinical endocrinology and metabolism.

[720]  N. Christensen,et al.  Hemodynamics in diabetic orthostatic hypotension. , 1981, The Journal of clinical investigation.

[721]  J. Segall Strategy of prevention: lessons from cardiovascular disease , 1981, British medical journal.

[722]  M. Shipley,et al.  CORONARY-HEART-DISEASE RISK AND IMPAIRED GLUCOSE TOLERANCE The Whitehall Study , 1980, The Lancet.

[723]  D. Ewing,et al.  The natural history of diabetic autonomic neuropathy. , 1980, The Quarterly journal of medicine.

[724]  Daniel L. McGee,et al.  Diabetes and cardiovascular disease. The Framingham study. , 1979, JAMA.

[725]  J. Stamler,et al.  Asymptomatic hyperglycemia and coronary heart disease. A series of papers by the International Collaborative Group, based on studies in fifteen populations. Introduction. , 1979, Journal of chronic diseases.

[726]  S. Punsar,et al.  Glucose tolerance and coronary heart disease: Helsinki policemen study. , 1979, Journal of chronic diseases.

[727]  M. Turina,et al.  [Percutaneous transluminal dilatation of chronic coronary stenoses. First experiences]. , 1978, Swiss medical weekly.

[728]  C. Lowy Diabetes and hypertension. , 1978, Lancet.

[729]  T. Deckert,et al.  Prognosis of diabetics with diabetes onset before the age of thirty-one. I. Survival, causes of death, and complications. , 1978, Diabetologia.

[730]  A. Sniderman,et al.  Low Density Lipoprotein: A METABOLIC PATHWAY FOR RETURN OF CHOLESTEROL TO THE SPLANCHNIC BED , 1978 .

[731]  L. Opie,et al.  Propranolol and experimental myocardial infarction: substrate effects. , 1976, Postgraduate medical journal.

[732]  W. Kannel,et al.  Role of diabetes in congestive heart failure: the Framingham study. , 1974, The American journal of cardiology.

[733]  W. Kannel,et al.  The natural history of congestive heart failure: the Framingham study. , 1971, The New England journal of medicine.

[734]  W. C. Sheldon,et al.  Reconstructive coronary artery surgery. Venous autograft technique. , 1970, JAMA.

[735]  F. Sones,et al.  Myocardial revascularization by internal mammary artery implant procedures. Clinical experience. , 1967, The Journal of thoracic and cardiovascular surgery.

[736]  V. Menkin DIABETES AND INFLAMMATION. , 1941, Science.